Our Safety Pharmacology investigators have recently completed a study on the effects of social housing on continuous myocardial contractility as part of standard preclinical cardiovascular evaluations.
Dr. David Hutto recently joined our team as the Chief Scientific Officer for the Safety Assessment division. Dr. Hutto will ensure the quality and alignment of the safety assessment sciences across all relevant units and sites within Charles River.
Repurposing known compounds or mechanisms may be a very effective way to improve the efficiency of pharmaceutical R&D. With emerging access to large pharmaceutical company compounds, there is a golden opportunity to investigate novel treatments.
Inspired by the Alzheimer's Association's nationwide fundraising event hosted annually on the summer solstice, Charles River’s Longest Day promoted Alzheimer’s disease education, brain health and physical activity at our sites globally.
Charles River has acquired Celsis International Ltd, a leading provider of rapid microbial detection systems for quality control testing in the biopharmaceutical and consumer products industries. The combination of Charles River and Celsis will drive significant value for our clients’ in-process and product release testing needs across a broad range of microbial detection applications.
ChanTest, a Charles River company, in collaboration with the FDA, is developing high-throughput assays to evaluate the pharmacology of tobacco product constituents and project their physiological impact.
We are pleased to announce the appointment of Joseph Murphy, PhD, and Martin Graf, PhD, to the positions of Director and Associate Director of Science and R&D Operations, respectively, at our oncology-focused site in North Carolina.
Charles River is pleased to announce our development of a new in vivo adventitious agent testing protocol that consolidates methods and reduces costs while meeting both US and European regulatory requirements.
We are excited to announce our newly available 36-plex mouse and 22-plex rat ProcartaPlex™ cytokine and chemokine immunoassays for discovery studies.
Charles River has recently validated the cuprizone model for the examination of both demyelination and remyelination for studies in multiple sclerosis.